Alzheimer’s Risk Tied to Single Gene: Gene Therapy Hope Emerges

For decades, Alzheimer’s disease has resisted effective treatment, often attributed to its complex and multifactorial nature. But a new study suggests a surprisingly dominant role for genetics, specifically the apolipoprotein E (APOE) gene, in determining risk. While lifestyle and environmental factors still play a part, the research indicates that the genetic hand dealt by APOE is the primary driver for most people and a staggering 99% of the population carries at least one version of the gene that can increase risk. This finding has ignited hope for a gene therapy approach that could dramatically reduce Alzheimer’s risk for a large segment of the population.

The APOE Gene and Alzheimer’s Risk: A Shifting Understanding

For years, the APOE gene was understood to have three variants – APOE2, APOE3, and APOE4 – with APOE2 considered protective, APOE4 increasing risk, and APOE3 being neutral. However, the recent study, published in Nature, challenges this understanding. Analyzing data from 450,000 individuals, researchers found that APOE3 isn’t neutral; it modestly increases risk, while carrying two copies of APOE2 offers almost complete protection against developing Alzheimer’s. This revised understanding is crucial, as it reframes the potential for genetic intervention.

The APOE protein’s primary function is transporting fats through the bloodstream, but it likewise interacts closely with amyloid-beta, a protein that forms plaques in the brain, a hallmark of Alzheimer’s disease. Research suggests that the APOE4 variant impairs fat processing in brain support cells called glia, leading to dysfunction and inflammation. It also appears to increase cell death and reduce the brain’s ability to adapt to oxidative stress. The protective APOE2 variant, conversely, seems to mitigate these harmful effects. Studies in lab dishes have further illuminated these mechanisms.

A Gene Therapy Target for Millions

Approximately 900,000 people in the United States carry the highest-risk form of APOE, according to Nolan Townsend, CEO of Lexeo Therapeutics, a company developing a gene therapy targeting the gene. This represents a substantial population, far exceeding the patient numbers for most existing gene therapies, which typically address rare genetic disorders. For example, spinal muscular atrophy affects roughly 1 in 15,000 live births in the US.

Lexeo Therapeutics is planning three clinical trials. The first aims to increase protective APOE gene variants in individuals with early Alzheimer’s and the highest-risk APOE4/APOE4 gene combination. A second, still in development, will introduce an enhanced version of APOE2 – the Christchurch variant – which has been linked to remarkable resilience against Alzheimer’s even in the presence of significant amyloid plaque buildup. A third trial will combine APOE2 introduction with a technique to suppress the expression of the APOE4 gene. Initial safety testing of the first approach has shown promising results, with reduced tau levels observed in participants. More details on the trials are available on Lexeo’s investor relations page.

Challenges and Considerations in Gene Therapy Development

While the potential is significant, several hurdles remain. Delivering gene therapies to the brain is complex. Adeno-associated viruses (AAVs) are currently the preferred delivery method, as they can cross the blood-brain barrier. However, maximizing penetration and ensuring the therapy reaches the correct brain regions are ongoing challenges. Lexeo Therapeutics is utilizing a cerebrospinal fluid injection to improve brain-wide delivery.

Demonstrating efficacy to regulatory bodies like the FDA also presents a challenge. Unlike the recent anti-amyloid antibody treatments, which were approved based on their ability to reduce amyloid plaques, the path to approval for gene therapies is less clear. Clinical trials are expensive and time-consuming, and demonstrating a clear link between genetic changes and cognitive improvement is crucial. Researchers are actively working to refine delivery methods and assessment tools to overcome these obstacles.

The Role of Anti-Amyloid Antibodies and Future Therapies

The advent of anti-amyloid antibodies like donanemab represents a step forward in Alzheimer’s treatment, but these drugs are not without drawbacks, including severe side effects like brain swelling and microbleeds. The patients most at risk from Alzheimer’s are also most vulnerable to these side effects. Gene therapy targeting APOE offers a potentially more preventative approach, aiming to reduce risk before significant brain damage occurs. However, experts emphasize that a single therapy is unlikely to be a complete solution. Dr. Shanshan Wang, an anesthesiologist at UC San Diego, suggests a combinatory approach, similar to cancer treatment, targeting multiple facets of the disease. She is currently working on a separate gene therapy aimed at protecting damaged neurons. More information about Dr. Wang’s research can be found on her UCSD profile.

The study authors concluded that APOE3 and APOE4 together are responsible for between 72% and 93% of Alzheimer’s disease cases, highlighting the significant impact of this single gene. However, it’s critical to remember that genetics is not destiny. Lifestyle factors and other genes likely contribute to the disease, and further research is needed to fully understand the interplay of these elements.

The development of APOE-targeted gene therapies represents a promising new avenue in the fight against Alzheimer’s disease. While challenges remain, the potential to significantly reduce risk for a large proportion of the population offers a beacon of hope for those at risk and their families. The next steps involve continued clinical trials, refinement of delivery methods, and a deeper understanding of the complex interplay between genetics, lifestyle, and disease progression.